^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

KO-2806

i
Other names: KO-2806
Associations
Company:
Kura Oncology
Drug class:
Farnesyl transferase inhibitor
Associations
12ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • HRAS mutation • HRAS overexpression
|
Cabometyx (cabozantinib tablet) • KO-2806
1year
FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=270, Recruiting, Kura Oncology, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • HRAS mutation • HRAS overexpression
|
Cabometyx (cabozantinib tablet) • KO-2806
over1year
New P1 trial • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • HRAS mutation • HRAS overexpression
|
Cabometyx (cabozantinib tablet) • KO-2806